Drugs / rV-PSA
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00004029 | Dec 1996 → May 2006 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00045227 | Aug 2002 → Oct 2007 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00005916 | Jun 2000 → Dec 2005 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rV-PSA | “recombinant vaccinia virus (rV) that expresses the prostate-specific antigen gene (rV-PSA)” PMID 16489082 ↗ Feb 20062“recombinant vaccinia virus expressing prostate-specific antigen (rV-PSA)” NCT00004029 ↗ |
| Action | Deplete | “Vaccines may make the body build an immune response to kill tumor cells.” NCT00045227 ↗ |
| Modality | Vaccine | “recombinant viral vaccine therapy” NCT00004029 ↗ |
| Route | Subcutaneous | “All patients receive recombinant vaccinia-prostate-specific antigen (PSA) vaccine subcutaneously (SC)” NCT00045227 ↗ |